Иммунные исследования
Открытый доступ
ISSN: 1745-7580
ISSN: 1745-7580
Stacy M*
High risk stage II colon cancer (CC) patients who will benefit from adjuvant treatment remains a clinical concern; however, no ideal model has been applied to clearly identify which suitable stage II CC patients should receive adjuvant chemotherapy. A previous study has provided an ideal and quantifiable model to identify suitable high risk stage II CC patients who should receive adjuvant chemotherapy after undergoing non-emergent surgery. This study is of importance; however, more factors should be taken into considerations to modify the prognostic model, which still requires further validation. To investigate whether cytokine-induced killer cells (CIK)/ dendritic cell (DC)-CIK therapy is able to improve the therapeutic efficacy of chemotherapy in gastric cancer. We conducted a systematic review in latest published papers from the sources of several databases. The effects (95% CIs) of chemotherapy were compared with those of chemotherapy in combination with CIK/DC-CIK immunotherapy.